Y-mAbs Therapeutics, Inc.
YMAB · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Market Cap | $204 | $200 | $351 | $587 |
| - Cash | $62 | $60 | $67 | $68 |
| + Debt | $3 | $1 | $1 | $1 |
| Enterprise Value | $145 | $140 | $285 | $520 |
| Revenue | $20 | $21 | $26 | $18 |
| % Growth | -6.6% | -21.1% | 43.5% | – |
| Gross Profit | $17 | $18 | $19 | $16 |
| % Margin | 86.4% | 85.6% | 70.4% | 87.8% |
| EBITDA | -$6 | -$5 | -$6 | -$8 |
| % Margin | -28.7% | -24.5% | -22% | -45.8% |
| Net Income | -$3 | -$5 | -$7 | -$7 |
| % Margin | -16.6% | -24.9% | -25.6% | -37.9% |
| EPS Diluted | -0.072 | -0.12 | -0.15 | -0.16 |
| % Growth | 40.4% | 20% | 6.3% | – |
| Operating Cash Flow | $2 | -$7 | -$2 | -$11 |
| Capital Expenditures | $0 | -$0 | $0 | $0 |
| Free Cash Flow | $2 | -$7 | -$2 | -$11 |